What Happened? : JointStem Sales Contract Maintained

NatureCell has decided to maintain its domestic sales contract for JointStem, its osteoarthritis treatment. This contract will remain in effect until the final ruling on the administrative litigation regarding the rejection of JointStem’s product license by the Ministry of Food and Drug Safety.

Why Does It Matter? : Potential FDA Approval vs. Domestic Rejection

The positive designation and potential approval from the US FDA is a significant indicator supporting the technological capabilities of JointStem. However, the domestic rejection raises uncertainty about its commercialization and sales in Korea. This conflicting situation is causing confusion among investors.

What’s Next? : A Glimmer of Hope Amidst Uncertainty

While maintaining the sales contract could positively impact stock prices in the short term, it remains unclear whether this will translate into actual profit generation. The future of NatureCell hinges on obtaining domestic and international product licenses for JointStem and its successful commercialization.

What Should Investors Do? : Proceed with Caution, Monitor Closely

  • Cautious Investment: Given the high level of uncertainty, a cautious investment approach is necessary.
  • Close Monitoring: Keep a close eye on news related to JointStem, particularly the outcome of the domestic administrative litigation and the FDA approval process in the US.
  • Profit Generation Confirmation: It’s crucial to confirm whether maintaining the sales contract leads to an actual increase in sales.
  • Financial Health Assessment: Evaluate NatureCell’s efforts to improve its financial structure.
  • Alternative Pipeline Check: Checking the development status of pipelines other than JointStem is also important.